NBRV

Stats

Summary

nabriva is a clinical-stage biopharmaceutical company engaged in the research and development of novel antibiotics to treat serious infections, with a focus on the pleuromutilin class of antibiotics. our goal is to become a fully integrated biopharmaceutical company focused on the research, development and commercialization of novel anti-infective products. nabriva was incorporated as a spin-off from sandoz gmbh antibiotics research institute (abri) in vienna, austria and commenced operations in february 2006. the new organization included small molecule assets, including pleuromutilin structure activity relationships (sar) knowledge and was focused on synthesis of pleuromutilins for systemic human use. following identification of our lead compound lefamulin and based on the clinical results of lefamulin for acute skin and skin structure infections. we believed that targeted in vitro spectrum of activity for the common pathogens causing community acquired bacterial pneumonia (cabp), wo

Market Cap: 4.55 Million

Primary Exchange: NASDAQ

Website: https://www.nabriva.com/

Shares Outstanding: 3.2 Million

Float: 0

Dividend: 0.0 (0.0%)

Beta: 0.33903088973007184

Sector: Manufacturing

Industry: Medicinal and Botanical Manufacturing

Ethical Flags

Longest drawdown: 2294 trading days

From: 2015-09-18 To: 2023-07-31

Lowest Point:

Ex-Date	Payment Date	Record Date	Declared Date	Amount	Flag	Dividend Type	Qualified	Indicated

Ex-Date	Declared Date	Record Date	Payment Date	Ratio	To Factor	For Factor